Table 1.
First author and year of publication, PICOS information, and oral manifestation reported in the 27 articles described patients with RAS or a history of RAS.
| Authors | Study Design | No. of Patients/ Controls |
Age Patients/ Controls |
Sex Patients/ Controls |
Diagnosis | Outcome RAS No. (%) |
|---|---|---|---|---|---|---|
| Acar et al. (2012) [20] | Cross-sectional | 35/ 35 |
13.7 (6–19) | 17M;18F | CD | 13 (37.1%)/4 (11.4%) |
| Ahmed et al. (2021) [21] | Cross-sectional | 118/ 40 |
26 (20–37.23)/ 28.5 (21.3–36.8) |
42M;76F 19M;21F |
CD | 44 (37.3%)/(12.5%) |
| Alsadat et al. (2021) [22] | Case-control | 104/ 104 |
10.67 ± 2.39 (6–14) 10.69 ± 2.36 |
52M;52F 52M;52F |
CD | 44 (42.3%)/(15.4%) |
| Bijelić et al. (2019) [23] | Case-control | 1 | CD | 1 RAS | ||
| Bramanti et al. (2014) [24] | Cross-sectional | 50/ 54 |
7.5 ± 4.4/ 8.8 ±2.9 |
22M;28F 22M;32F |
CD | 26 (52%)/4 (7.4%) |
| Bucci et al. (2006) [25] | Case-control | 72/ 162 |
9.05 ± 1.97 | 15M;57F 65M;97F |
CD | 24 (33.3%)/38 (23.4%) |
| Campisi et al. (2007) [26] | Case-control | 197/ 413 |
19.09 (2–75)/ (2–77) |
73M;124F 163M;250F |
CD | 37 (19%)/3 (1%) |
| Cruz et al. (2018) [27] | Case-control | 40/ 40 |
16.50 | 12M;28F 28.7%M;71.3% F |
CD | 15 (43.9%)/32 (56.1%) |
| da Silva et al. (2008) [28] | Case report | 1 | 39 | 1F | CD | 1 (100%) |
| de Carvalho et al. (2015) [29] | Case-control | 52/ 52 |
11.59± 5.74/ 11.48 (5.26) |
18M;34F 23M;29F |
CD | 21 (40.38%)/9 (17.31) |
| Elbek-Cubukcu et al. (2023) [30] | Cross-sectional | 62/ 64 |
9.17± 4.39 12.12± 3.3 |
20M;42F 20M;44F |
CD | 19 (30.6%)/0 |
| Erriu et al. (2011) [31] | Observational study | 98 | 35.92 (7–77) | 23M;75F | CD | 38 (38.77%) |
| Kovačić et al. (2021) [32] | Case report | 1 | 41 | 1F | CD | 1 (100%) |
| Lähteenoja et al. (1998) [33] | Cross-sectional | 136/ 30 |
46.9 ± 9.8/ 47.9 ± 14.3 |
15M;15F 11M;19F |
CD | 1/0 RAS; 12/0 mucosal ulceration |
| Liu et al. (2022) [34] | Cross-sectional | 20/ 20 |
49.2 ± 15.5 48.0 ± 12.7 |
4M;16F 2M;18F |
CD | 17 (85%)/7 (35%) |
| Ludovichetti et al. (2022) [35] | Retrospective cohort |
38/ 38 |
(6 to 14) | 11M;27F 12M;26F |
CD | 9 (23.7%)/3 (7.9%) |
| Macho et al. (2019) [36] | Case-control | 80/ 80 |
13.3 (6 to 18) | 32M;48F 35M;45F |
CD | 45 (56.3%)/16 (20%) |
| Mina et al. (2008) [37] | Case-control | 52/ 23 |
7.9 (4–12) | CD | 19 (63.15%)/0 (0%) | |
| Mina et al. (2012) [38] | Observational longitudinal | 25/ 25 |
CD | 19 (63.15%) | ||
| Moreau et al. (2020) [39] | Retrospective cohort | 28/ 59 |
8 (3 to 12)/ 7.2 (1 to 12) |
9M;19F/ 30M;29F |
CD | 14 (50%)/12 (21.82%) |
| Nota et al. (2020) [40] | Structured questionnaire (survey) |
237 | (15 to 56) | 55M;182F | CD | 41 (17.3%) |
| Procaccini et al. (2007) [41] | Case-control | 50/ 50 |
(3 to 25) | CD | 18 (36%)/6 (12%) | |
| Saraceno et al. (2016) [42] | Cross-sectional | 83/83 | 9.15 (±2.12) | 21M;62F | CD | 58 (69%) |
| Shahraki et al. (2019) [43] | Case-control | 65/ 60 |
8.9 (3–16) | 23M;42F 31M;29F |
CD | 11 (17%)/8 (13%) |
| Yazdanbod et al. (2014) [44] | Cross-sectional | 2 | 29 | 2F | CD | 2 (100%) RAS |
| Yilmaz et al. (2020) [45] | Retrospective cohort |
3 | CD | 3 (100%) RAS | ||
| Zoumpoulakis et al. (2019) [11] | Case-control | 45/ 45 |
10.3 ± 4.1 10.3 ± 4.05 |
15M;30F | CD | 18 (40%)/2 (4.4%) |